DARE vs TPVG vs HRZN vs HTGC vs ARCC

For growth investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). Horizon Technology Finance Corporation (HRZN) offers the better valuation at 4. 3x trailing P/E (6. 1x forward), making it the more compelling value choice. Analysts rate Hercules Capital, Inc. (HTGC) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Horizon Technology Finance Corporation (HRZN) is the cheapest at 4.

3x versus Ares Capital Corporation at 10. 2x. On forward P/E, Horizon Technology Finance Corporation is actually cheaper at 6. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Horizon Technology Finance Corporation wins at 0. 26x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Ares Capital Corporation (ARCC) delivered a total return of +47.

0%, compared to -82. 4% for Daré Bioscience, Inc. (DARE). Over 10 years, the gap is even starker: HTGC returned +171. 6% versus DARE's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Daré Bioscience, Inc.

(DARE) is the lower-risk stock at 0. 48β versus TriplePoint Venture Growth BDC Corp. 's 0. 83β — meaning TPVG is approximately 74% more volatile than DARE relative to the S&P 500. On balance sheet safety, Hercules Capital, Inc. (HTGC) carries a lower debt/equity ratio of 104% versus 149% for Horizon Technology Finance Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.

(TPVG) is pulling ahead at 36. 6% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: Horizon Technology Finance Corporation grew EPS 756. 3% year-over-year, compared to -23. 8% for Ares Capital Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hercules Capital, Inc.

(HTGC) is the more profitable company, earning 62. 1% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 62. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — HTGC leads at 87. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Horizon Technology Finance Corporation (HRZN) is the more undervalued stock at a PEG of 0. 26x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Horizon Technology Finance Corporation (HRZN) trades at 6. 1x forward P/E versus 9. 9x for Ares Capital Corporation — 3. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TPVG: 49. 4% to $8. 95.

In this comparison, HRZN (27.

8% yield), TPVG (17. 1% yield), HTGC (8. 6% yield), ARCC (2. 0% yield) pay a dividend. DARE does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Hercules Capital, Inc.

(HTGC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69), 8. 6% yield, +171. 6% 10Y return). Both have compounded well over 10 years (HTGC: +171. 6%, DARE: -99. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DARE (Healthcare) and TPVG (Financial Services) and HRZN (Financial Services) and HTGC (Financial Services) and ARCC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DARE is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; HRZN is a small-cap high-growth stock; HTGC is a small-cap high-growth stock; ARCC is a mid-cap high-growth stock. TPVG, HRZN, HTGC, ARCC pay a dividend while DARE does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.